84332-02-5

Usage

Uses

Used in Organic Synthesis:
3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester is used as a building block in organic synthesis for the creation of various pharmaceutical compounds. Its unique structure and reactivity allow for the development of new and innovative molecules with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester serves as a key intermediate in the synthesis of pharmaceutical compounds. Its presence in the molecular structure can impart specific biological activities, making it a valuable component in the design and development of new drugs.
Used in Drug Development:
3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester has potential applications in the development of new drugs due to its unique structure and reactivity. Its incorporation into drug molecules can lead to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Development:
In addition to pharmaceutical applications, 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester may also be utilized in the development of new agrochemicals. Its unique chemical properties can contribute to the creation of innovative compounds with potential applications in agriculture, such as pesticides or herbicides.

Upstream product

• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 124-41-4 sodium methylate 
• 162371-83-7 6-chloro-4-hydroxy-nicotinic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 

Downstream Products

• 1246765-64-9 (R)-6-(1-(3-chloro-4-cyanophenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methoxynicotinic acid 
• 1256823-05-8 6-chloro-4-methoxypyridine-3-carbaldehyde 
• 1263059-66-0 (6-chloro-4-methoxypyridin-3-yl)methanol 
• 1256819-61-0 methyl 6-bromo-4-methoxy pyridine-3-carboxylate 
• 716362-10-6 6-chloro-4-methoxypyridine-3-carboxylic acid 
• 1173177-02-0 1-((R)-4-benzoyl-2-methylpiperazin-1-yl)-2-[6-chloro-4-methoxypyridin-3-yl]ethane-1,2-dione 
• 84332-04-7 2-(2-amino-4-methoxy-5-pyridyl-carboxamidomethyl)-1-ethylpyrrolidine 

Relevant academic research and scientific papers

1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

Preparation method of 6-chloro-4-hydroxypyridine-3-carbaldehyde

The invention provides a preparation method of 6-chloro-4-hydroxypyridine-3-carbaldehyde. The final product, namely, 6-chloro-4-hydroxypyridine-3-carbaldehyde, is obtained through six-step reactions including ring closure, chlorination, etherification, reduction, oxidation and hydrolysis. The synthesis method is simple and easy to operate, a synthesis route is provided for product synthesis, theoretical and experimental bases are provided for industrial production, three wastes polluting the environment are not produced in the synthesis process, and the preparation method is very environment-friendly and suitable for large-scale industrial production. The synthesized product has high purity and yield and the production cost is low.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) aDNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionisin g radiation.

Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors

Inhibitors of checkpoint kinase 1 (CHK1) are of current interest as potential antitumor agents, but the most advanced inhibitor series reported to date are not orally bioavailable. A novel series of potent and orally bioavailable 3-alkoxyamino-5-(pyridin-

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

PIPERIDINE DERIVATIVES OR SALTS THEREOF

[Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS

The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing, said, inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).